Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10927207 | 0.81 | ENPP2 (0.48) | RXFP1CASP3KMT2AADRA1DADRA1A | |
| SCHEMBL1978691 | 0.79 | MAOB (0.55) | MAOBPDCD1CD274MRGPRX4PTGER1 | |
| SCHEMBL8409660 | 0.77 | HTR1A (0.59) | MAOBMRGPRX4PTGER1ALDH1A1 | |
| SCHEMBL8676493 | 0.77 | MAOB (0.55) | MAOBMRGPRX4PTGER1ALDH1A1PTGDR2 | |
| SCHEMBL6554874 | 0.77 | MAOB (0.55) | MAOBMRGPRX4PTGER1ALDH1A1PTGDR2 | |
| SCHEMBL6212565 | 0.77 | MAOB (0.55) | MAOBMRGPRX4PTGER1 | |
| SCHEMBL5089130 | 0.76 | MRGPRX4 (0.53) | MAOBMRGPRX4PTGER1PTGDR2 | |
| SCHEMBL7894114 | 0.76 | ADRA1D (0.43) | RXFP1CASP3KMT2AADRA1DADRA1A | |
| SCHEMBL5901031 | 0.75 | RXFP1 (0.53) | MAOBRXFP1CASP3KMT2AADRA1D | |
| Hydrochloric Acid SCHEMBL5098921 | 0.75 | MRGPRX4 (0.52) | MAOBMRGPRX4PTGER1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390357-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-05 | — | — | US | disclosed |
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062778-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | SERPINC1, TFPI, F2 | MAOB 743/4885GRM5 2870/4885PDCD1 3745/4885 |
| US-20020151534-A1 | Antithrombotic compounds | SERPINC1, PF4, F2 | MAOB 815/4885GRM5 1584/4885PDCD1 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.